Average Co-Inventor Count = 5.43
ph-index = 40
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Rigel Pharmaceuticals, Incorporated (292 from 485 patents)
2. Chemocentryx, Inc. (45 from 214 patents)
3. Arlo Technologies, Inc. (9 from 97 patents)
4. Chiron Corporation (8 from 656 patents)
5. Other (4 from 832,347 patents)
6. University of California (3 from 15,331 patents)
7. Bristol-myers Squibb Compnay (3 from 3,663 patents)
8. Array Biopharma Inc. (3 from 328 patents)
9. Novartis Ag (1 from 3,915 patents)
10. Bristol Meyers Squibb Company (1 from 41 patents)
11. Neutrino8, Inc. (1 from 7 patents)
12. Rigl Pharmaceutical, Inc. (1 from 1 patent)
13. Rogel Pharmaceuticals, Inc. (1 from 1 patent)
367 patents:
1. 12417362 - Dynamic image based contactless instructions for an electronic monitoring system
2. 12368597 - Method and system for the secure onboarding of low energy peripheral devices
3. 12227508 - TGF-β inhibitors
4. 12194032 - Method of treating focal segmental glomerulosclerosis
5. 12184741 - Method to securely update over-the-air firmware
6. 12148277 - Electronic monitoring system using push notifications with custom audio alerts
7. 12139475 - 2-oxindole compounds
8. 12043620 - Benzazole compounds and methods for making and using the compounds
9. 12011439 - Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors
10. 11993594 - IRAK inhibitors and method for making and using
11. 11986466 - Methods of treating solid tumors with CCR2 antagonists
12. 11939317 - Amide compounds and method for making and using
13. 11941320 - Electronic monitoring system having modified audio output
14. 11883391 - Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies
15. 11872217 - Indanes as PD-L1 inhibitors